B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.

Published on Jun 11, 2021in Immunology7.397
路 DOI :10.1111/IMM.13384
Yu Zhao11
Estimated H-index: 11
(Nantong University),
Yuejiao Cao2
Estimated H-index: 2
(Nantong University)
+ 4 AuthorsXiaorong Zhou5
Estimated H-index: 5
(Nantong University)
Sources
Abstract
Loss of the B2M gene is associated with tumor immune escape and resistance to immunotherapy. However, genetic alterations of the B2M gene are rare. We performed an integrative analysis of the mutational and transcriptional profiles of large cohorts of non-small-cell lung cancer (NSCLC) patients and found that epigenetic downregulation of B2M is common. B2M-low tumors exhibit a suppressive immune microenvironment characterized by reduced infiltration of immune cells of various lineages; in B2M-high tumors, more T and natural killer (NK) cells are present, but their activities are constrained by immune checkpoint molecules, indicating the diverse mechanisms of immune evasion. High levels of B2M mRNA, but not PD-L1, are correlated with an enhanced response to PD-1-based immunotherapy, suggesting its value for immunotherapy response prediction in solid tumors. Notably, a high tumor mutation burden (TMB) is associated with low B2M expression, which may explain the poor predictive value of the TMB in some situations. In syngeneic mouse models, genetic ablation of B2M in tumor cells causes resistance to PD-1-based immunotherapy, and B2M knockdown also diminishes the therapeutic efficacy. Moreover, forced expression of B2M in tumor models improves the response to immunotherapy, suggesting that B2M levels have significant impacts on treatment outcomes. Finally, we provide insight into the roles of transcription factors and KRAS mutations in B2M expression and the anticancer immune response. In conclusion, genetic and epigenetic regulation of B2M fundamentally shapes the NSCLC immune microenvironment and may determine the response to checkpoint blockade-based immunotherapy.
馃摉 Papers frequently viewed together
201823.06Gut
23 Authors (Yue Zhao, ..., Qingfeng Chen)
References72
Newest
#1Ningshan Li (CQMU: Chongqing Medical University)H-Index: 2
#2Jiawei TangH-Index: 1
Last. Zhi-biao Wang (CQMU: Chongqing Medical University)H-Index: 4
view all 11 authors...
Abstract Cancer immunotherapy holds tremendous promise as a strategy for eradicating solid tumors, and its therapeutic effect highly relies on sufficient CD8+ T cells infiltration. Here, we demonstrate that ultrasound stimulated microbubble cavitation (USMC) promotes tumor perfusion, thereby increasing CD8+ T cells infiltration and anti-PD-L1 antibody delivery, then further enhancing the PD-L1 blockade of MC38 colon cancer in mice. Firstly, we optimized the mechanic index (MI) of ultrasound, and...
Source
#1Takaaki ObaH-Index: 4
#2Mark D. LongH-Index: 15
Last. Fumito ItoH-Index: 15
view all 8 authors...
The ability of cancer cells to ensure T-cell exclusion from the tumor microenvironment is a significant mechanism of resistance to anti-PD-1/PD-L1 therapy. Evidence indicates crucial roles of Batf3-dependent conventional type-1 dendritic cells (cDC1s) for inducing antitumor T-cell immunity; however, strategies to maximize cDC1 engagement remain elusive. Here, using multiple orthotopic tumor mouse models resistant to anti-PD-L1-therapy, we are testing the hypothesis that in situ induction and act...
Source
#8Corey J. Langer (UPenn: University of Pennsylvania)H-Index: 8
Background Limited data exist on the role of alterations in HLA Class I antigen processing and presentation machinery in mediating response to immune checkpoint blockade (ICB). Methods This retrospective cohort study analyzed transcriptional profiles from pre-treatment tumor samples of 51 chemotherapy-refractory advanced non-small cell lung cancer (NSCLC) patients and two independent melanoma cohorts treated with ICB. An antigen processing machinery (APM) score was generated utilizing eight gene...
Source
#1Sandrine AspeslaghH-Index: 20
#2Roman M. Chabanon (ICR: Institute of Cancer Research)H-Index: 6
Last. Sophie Postel-Vinay (French Institute of Health and Medical Research)H-Index: 35
view all 4 authors...
Abstract The advent of immune checkpoint blockers (ICB) has revolutionized patient outcome in many tumor types. However, only a minority of patients truly benefits from these therapies and displays a durable and robust anti-tumor response that translates into improved outcome. Thorough mechanistic preclinical studies and comprehensive investigations performed in tumor biopsies of patients treated with ICB have unveiled multiple resistance mechanisms involving both tumor-intrinsic and tumor-extri...
Source
#1David S. HongH-Index: 64
#2Marwan FakihH-Index: 55
Last. Bob T. LiH-Index: 38
view all 34 authors...
Abstract Background No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non鈥搒mall-cell lung cancers (NSCLCs) and in 1 to 3% of colorect...
Source
#1Simona Sivori (UniGe: University of Genoa)H-Index: 48
#2Mariella Della Chiesa (UniGe: University of Genoa)H-Index: 29
Last. Lorenzo Moretta (Boston Children's Hospital)H-Index: 148
view all 11 authors...
The highly destructive mechanisms by which the immune system faces microbial infections is under the control of a series of inhibitory receptors. While most of these receptors prevent unwanted/excessive responses of individual effector cells, others play a more general role in immunity, acting as true inhibitory checkpoints controlling both innate and adaptive immunity. Regarding human NK cells, their function is finely regulated by HLA-class I-specific inhibitory receptors which allow discrimin...
Source
#1Xiaomin Cai (Nanjing Medical University)H-Index: 6
#2Bin Wei (Nanjing Medical University)H-Index: 3
Last. Yanhong Gu (Nanjing Medical University)H-Index: 25
view all 11 authors...
Increasing studies confirm that anti-angiogenesis can increase the effectiveness of immunotherapy. In this study, we found that an angiogenesis inhibitor apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression. Apatinib treatment upregulated PD-L1 expression in various colon cancer cells both at the mRNA and protein levels. Further, apatinib-treated cancer cells hampered activation and IFN-纬 secretion of T cells in the co-culture system, which was reversed by ...
Source
#1Alicja Sznarkowska (University of Gda艅sk)H-Index: 7
#2Sara Mikac (University of Gda艅sk)H-Index: 2
Last. Magdalena Pilch (University of Gda艅sk)H-Index: 2
view all 3 authors...
Viral-derived elements and non-coding RNAs that build up 鈥渏unk DNA鈥 allow for flexible and context-dependent gene expression. They are extremely dense in the MHC region, accounting for flexible expression of the MHC I, II, and III genes and adjusting the level of immune response to the environmental stimuli. This review brings forward the viral-mediated aspects of the origin and evolution of adaptive immunity and aims to link this perspective with the MHC class I regulation. The complex regulato...
Source
#1Jo Waaler (University of Oslo)H-Index: 13
#2Line Mygland (University of Oslo)H-Index: 4
Last. Stefan Krauss (University of Oslo)H-Index: 59
view all 19 authors...
The development of immune checkpoint inhibitors represents a major breakthrough in cancer therapy. Nevertheless, a substantial number of patients fail to respond to checkpoint pathway blockade. Evidence for WNT/尾-catenin signaling-mediated immune evasion is found in a subset of cancers including melanoma. Currently, there are no therapeutic strategies available for targeting WNT/尾-catenin signaling. Here we show that a specific small-molecule tankyrase inhibitor, G007-LK, decreases WNT/尾-catenin...
Source
#1Jenny H. Lee (Macquarie University)H-Index: 17
#2Elena Shklovskaya (Macquarie University)H-Index: 17
Last. Helen Rizos (Macquarie University)H-Index: 52
view all 18 authors...
Transcriptomic signatures designed to predict melanoma patient responses to PD-1 blockade have been reported but rarely validated. We now show that intra-patient heterogeneity of tumor responses to PD-1 inhibition limit the predictive performance of these signatures. We reasoned that resistance mechanisms will reflect the tumor microenvironment, and thus we examined PD-1 inhibitor resistance relative to T-cell activity in 94 melanoma tumors collected at baseline and at time of PD-1 inhibitor pro...
Source
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.